Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 157

1.

Inflammatory Response 24 h Post-Exercise in Youth with Juvenile Idiopathic Arthritis.

Rochette E, Merlin E, Hourdé C, Evrard B, Peraira B, Echaubard S, Duché P.

Int J Sports Med. 2018 Aug 17. doi: 10.1055/a-0640-9063. [Epub ahead of print]

PMID:
30119133
2.

Diagnostic capability of a next-generation, ultra-miniaturized ultrasound system in patients with cardiopulmonary compromise assessed using basic critical care echocardiography.

Goudelin M, Evrard B, Dalmay F, Padilla AH, Gonzalez C, Lafon T, Daix T, Fedou AL, François B, Vignon P.

Intensive Care Med. 2018 May 31. doi: 10.1007/s00134-018-5225-6. [Epub ahead of print] No abstract available.

PMID:
29855665
3.

Short-term effect of outdoor mould spore exposure on prescribed allergy medication sales in Central France.

Caillaud D, Cheriaux M, Martin S, Ségala C, Dupuy N, Evrard B, Thibaudon M.

Clin Exp Allergy. 2018 Jul;48(7):837-845. doi: 10.1111/cea.13160. Epub 2018 May 17.

PMID:
29698555
4.

Cationic Liposomes Carrying siRNA: Impact of Lipid Composition on Physicochemical Properties, Cytotoxicity and Endosomal Escape.

Lechanteur A, Sanna V, Duchemin A, Evrard B, Mottet D, Piel G.

Nanomaterials (Basel). 2018 Apr 24;8(5). pii: E270. doi: 10.3390/nano8050270.

5.

Peanut gastrointestinal delivery oral immunotherapy in adolescents: Results of the build-up phase of a randomized, double-blind, placebo-controlled trial (PITA study).

Fauquert JL, Michaud E, Pereira B, Bernard L, Gourdon-Dubois N, Rouzaire PO, Rochette E, Merlin E, Evrard B; PITA Group.

Clin Exp Allergy. 2018 Jul;48(7):862-874. doi: 10.1111/cea.13148. Epub 2018 May 29.

PMID:
29665158
6.

An update on molecular cat allergens: Fel d 1 and what else? Chapter 1: Fel d 1, the major cat allergen.

Bonnet B, Messaoudi K, Jacomet F, Michaud E, Fauquert JL, Caillaud D, Evrard B.

Allergy Asthma Clin Immunol. 2018 Apr 10;14:14. doi: 10.1186/s13223-018-0239-8. eCollection 2018. Review.

7.

Ara h 2 basophil activation test does not predict clinical reactivity to peanut.

Chapuis A, Thevenot J, Coutant F, Messaoudi K, Michaud E, Pereira B, Rochette E, Gourdon-Dubois N, Merlin E, Fauquert JL, Evrard B, Rouzaire P.

J Allergy Clin Immunol Pract. 2018 Feb 2. pii: S2213-2198(18)30048-5. doi: 10.1016/j.jaip.2018.01.021. [Epub ahead of print] No abstract available.

PMID:
29410305
8.

RSV-hRV co-infection is a risk factor for recurrent bronchial obstruction and early sensitization 3 years after bronchiolitis.

Amat F, Plantard C, Mulliez A, Petit I, Rochette E, Verdan M, Henquell C, Labbé G, Heraud MC, Evrard B, Labbé A.

J Med Virol. 2018 May;90(5):867-872. doi: 10.1002/jmv.25037. Epub 2018 Feb 15.

PMID:
29380391
9.

Limited value of end-expiratory inferior vena cava diameter to predict fluid responsiveness impact of intra-abdominal pressure.

Vieillard-Baron A, Evrard B, Repessé X, Maizel J, Jacob C, Goudelin M, Charron C, Prat G, Slama M, Geri G, Vignon P.

Intensive Care Med. 2018 Feb;44(2):197-203. doi: 10.1007/s00134-018-5067-2. Epub 2018 Jan 22.

PMID:
29356854
10.

Activation state of circulating eosinophils in nasal polyposis.

Dupuch V, Tridon A, Ughetto S, Walrand S, Bonnet B, Dubray C, Virlogeux A, Vasson MP, Saroul N, Mom T, Gilain L, Evrard B.

Int Forum Allergy Rhinol. 2018 May;8(5):584-591. doi: 10.1002/alr.22079. Epub 2018 Jan 15.

PMID:
29334431
11.

Safety and tolerance of cidofovir as a 2% gel for local application in high-grade cervical intraepithelial neoplasia: A phase 1 investigation.

Bossens M, Jost M, Van Pachterbeke C, De Maertelaer V, Simon P, Frankenne F, Hubert P, Evrard B, Snoeck R.

Int J Clin Pharmacol Ther. 2018 Mar;56(3):134-141. doi: 10.5414/CP203126.

PMID:
29319498
12.

Development of an analytical method for crystalline content determination in amorphous solid dispersions produced by hot-melt extrusion using transmission Raman spectroscopy: A feasibility study.

Netchacovitch L, Dumont E, Cailletaud J, Thiry J, De Bleye C, Sacré PY, Boiret M, Evrard B, Hubert P, Ziemons E.

Int J Pharm. 2017 Sep 15;530(1-2):249-255. doi: 10.1016/j.ijpharm.2017.07.052. Epub 2017 Jul 23.

PMID:
28746834
13.

Changes in membrane biophysical properties induced by the Budesonide/Hydroxypropyl-β-cyclodextrin complex.

Dos Santos AG, Bayiha JC, Dufour G, Cataldo D, Evrard B, Silva LC, Deleu M, Mingeot-Leclercq MP.

Biochim Biophys Acta. 2017 Oct;1859(10):1930-1940. doi: 10.1016/j.bbamem.2017.06.010. Epub 2017 Jun 20.

14.

Global approach for the validation of an in-line Raman spectroscopic method to determine the API content in real-time during a hot-melt extrusion process.

Netchacovitch L, Thiry J, De Bleye C, Dumont E, Cailletaud J, Sacré PY, Evrard B, Hubert P, Ziemons E.

Talanta. 2017 Aug 15;171:45-52. doi: 10.1016/j.talanta.2017.04.060. Epub 2017 Apr 26.

PMID:
28551152
15.

Development and evaluation of injectable nanosized drug delivery systems for apigenin.

Karim R, Palazzo C, Laloy J, Delvigne AS, Vanslambrouck S, Jerome C, Lepeltier E, Orange F, Dogne JM, Evrard B, Passirani C, Piel G.

Int J Pharm. 2017 Nov 5;532(2):757-768. doi: 10.1016/j.ijpharm.2017.04.064. Epub 2017 Apr 27.

PMID:
28456651
16.

Promoting Vaginal Distribution of E7 and MCL-1 siRNA-Silencing Nanoparticles for Cervical Cancer Treatment.

Lechanteur A, Furst T, Evrard B, Delvenne P, Piel G, Hubert P.

Mol Pharm. 2017 May 1;14(5):1706-1717. doi: 10.1021/acs.molpharmaceut.6b01154. Epub 2017 Apr 7.

PMID:
28350964
17.

In vitro biphasic dissolution tests and their suitability for establishing in vitro-in vivo correlations: A historical review.

Pestieau A, Evrard B.

Eur J Pharm Sci. 2017 May 1;102:203-219. doi: 10.1016/j.ejps.2017.03.019. Epub 2017 Mar 15. Review.

PMID:
28315463
18.

The protein expression landscape of mitosis and meiosis in diploid budding yeast.

Becker E, Com E, Lavigne R, Guilleux MH, Evrard B, Pineau C, Primig M.

J Proteomics. 2017 Mar 6;156:5-19. doi: 10.1016/j.jprot.2016.12.016. Epub 2017 Jan 3.

19.

PEGylated and Functionalized Aliphatic Polycarbonate Polyplex Nanoparticles for Intravenous Administration of HDAC5 siRNA in Cancer Therapy.

Frère A, Baroni A, Hendrick E, Delvigne AS, Orange F, Peulen O, Dakwar GR, Diricq J, Dubois P, Evrard B, Remaut K, Braeckmans K, De Smedt SC, Laloy J, Dogné JM, Feller G, Mespouille L, Mottet D, Piel G.

ACS Appl Mater Interfaces. 2017 Jan 25;9(3):2181-2195. doi: 10.1021/acsami.6b15064. Epub 2017 Jan 11.

PMID:
28029254
20.

Sampling only ten microliters of whole blood for the quantification of poorly soluble drugs: Itraconazole as case study.

Thiry J, Evrard B, Nys G, Fillet M, Kok MGM.

J Chromatogr A. 2017 Jan 6;1479:161-168. doi: 10.1016/j.chroma.2016.12.009. Epub 2016 Dec 6.

PMID:
27955892
21.

Bioavailability enhancement of itraconazole-based solid dispersions produced by hot melt extrusion in the framework of the Three Rs rule.

Thiry J, Kok MG, Collard L, Frère A, Krier F, Fillet M, Evrard B.

Eur J Pharm Sci. 2017 Mar 1;99:1-8. doi: 10.1016/j.ejps.2016.12.001. Epub 2016 Dec 9.

PMID:
27951411
22.

Evaluation of different in vitro dissolution tests based on level A in vitro-in vivo correlations for fenofibrate self-emulsifying lipid-based formulations.

Pestieau A, Lebrun S, Cahay B, Brouwers A, Streel B, Cardot JM, Evrard B.

Eur J Pharm Biopharm. 2017 Mar;112:18-29. doi: 10.1016/j.ejpb.2016.10.030. Epub 2016 Nov 16. No abstract available.

PMID:
27865930
23.

Continuous production of itraconazole-based solid dispersions by hot melt extrusion: Preformulation, optimization and design space determination.

Thiry J, Lebrun P, Vinassa C, Adam M, Netchacovitch L, Ziemons E, Hubert P, Krier F, Evrard B.

Int J Pharm. 2016 Dec 30;515(1-2):114-124. doi: 10.1016/j.ijpharm.2016.10.003. Epub 2016 Oct 5.

PMID:
27720874
24.

Oral probiotic treatment of Lactobacillus rhamnosus Lcr35® prevents visceral hypersensitivity to a colonic inflammation and an acute psychological stress.

Darbaky Y, Evrard B, Patrier S, Falenta J, Garcin S, Tridon A, Dapoigny M, Silberberg C, Nivoliez A, Diop L.

J Appl Microbiol. 2017 Jan;122(1):188-200. doi: 10.1111/jam.13320. Epub 2016 Nov 21.

PMID:
27718511
25.

Hot-melt extrusion as a continuous manufacturing process to form ternary cyclodextrin inclusion complexes.

Thiry J, Krier F, Ratwatte S, Thomassin JM, Jerome C, Evrard B.

Eur J Pharm Sci. 2017 Jan 1;96:590-597. doi: 10.1016/j.ejps.2016.09.032. Epub 2016 Sep 26.

PMID:
27687637
26.

Efficacy of rituximab and plasmapharesis in an adult patient with antifactor H autoantibody-associated hemolytic uremic syndrome: A case report and literature review.

Deville C, Garrouste C, Coppo P, Evrard B, Lautrette A, Heng AE.

Medicine (Baltimore). 2016 Sep;95(39):e5007. doi: 10.1097/MD.0000000000005007. Review.

27.

PEGylation of lipoplexes: The right balance between cytotoxicity and siRNA effectiveness.

Lechanteur A, Furst T, Evrard B, Delvenne P, Hubert P, Piel G.

Eur J Pharm Sci. 2016 Oct 10;93:493-503. doi: 10.1016/j.ejps.2016.08.058. Epub 2016 Sep 1.

PMID:
27593989
28.

Capillary electrophoresis method to determine siRNA complexation with cationic liposomes.

Furst T, Bettonville V, Farcas E, Frere A, Lechanteur A, Evrard B, Fillet M, Piel G, Servais AC.

Electrophoresis. 2016 Oct;37(20):2685-2691. doi: 10.1002/elps.201600249. Epub 2016 Aug 4.

PMID:
27396918
29.

Freeze-dried mucoadhesive polymeric system containing pegylated lipoplexes: Towards a vaginal sustained released system for siRNA.

Furst T, Dakwar GR, Zagato E, Lechanteur A, Remaut K, Evrard B, Braeckmans K, Piel G.

J Control Release. 2016 Aug 28;236:68-78. doi: 10.1016/j.jconrel.2016.06.028. Epub 2016 Jun 18.

PMID:
27329774
30.

Selection of a discriminant and biorelevant in vitro dissolution test for the development of fenofibrate self-emulsifying lipid-based formulations.

Pestieau A, Krier F, Brouwers A, Streel B, Evrard B.

Eur J Pharm Sci. 2016 Sep 20;92:212-9. doi: 10.1016/j.ejps.2016.04.038. Epub 2016 May 8.

PMID:
27169683
31.

A simple calibration approach based on film-casting for confocal Raman microscopy to support the development of a hot-melt extrusion process.

Netchacovitch L, Thiry J, De Bleye C, Dumont E, Dispas A, Hubert C, Krier F, Sacré PY, Evrard B, Hubert P, Ziemons E.

Talanta. 2016 Jul 1;154:392-9. doi: 10.1016/j.talanta.2016.03.080. Epub 2016 Mar 26.

PMID:
27154691
32.

Slight Pro-Inflammatory Immunomodulation Properties of Dendritic Cells by Gardnerella vaginalis: The "Invisible Man" of Bacterial Vaginosis?

Bertran T, Brachet P, Vareille-Delarbre M, Falenta J, Dosgilbert A, Vasson MP, Forestier C, Tridon A, Evrard B.

J Immunol Res. 2016;2016:9747480. doi: 10.1155/2016/9747480. Epub 2016 Feb 17.

33.

Design of Ionizable Lipids To Overcome the Limiting Step of Endosomal Escape: Application in the Intracellular Delivery of mRNA, DNA, and siRNA.

Habrant D, Peuziat P, Colombani T, Dallet L, Gehin J, Goudeau E, Evrard B, Lambert O, Haudebourg T, Pitard B.

J Med Chem. 2016 Apr 14;59(7):3046-62. doi: 10.1021/acs.jmedchem.5b01679. Epub 2016 Mar 17.

PMID:
26943260
34.

Binding Potency of Heparin Immobilized on Activated Charcoal for DNA Antibodies.

Snezhkova EA, Tridon A, Evrard B, Nikolaev VG, Uvarov VY, Tsimbalyuk RS, Ivanuk AA, Komov VV, Sakhno LA.

Bull Exp Biol Med. 2016 Feb;160(4):444-7. doi: 10.1007/s10517-016-3192-x. Epub 2016 Feb 23.

PMID:
26902353
35.

Nanocarriers for the treatment of glioblastoma multiforme: Current state-of-the-art.

Karim R, Palazzo C, Evrard B, Piel G.

J Control Release. 2016 Apr 10;227:23-37. doi: 10.1016/j.jconrel.2016.02.026. Epub 2016 Feb 16. Review.

PMID:
26892752
36.

Investigation of a suitable in vitro dissolution test for itraconazole-based solid dispersions.

Thiry J, Broze G, Pestieau A, Tatton AS, Baumans F, Damblon C, Krier F, Evrard B.

Eur J Pharm Sci. 2016 Mar 31;85:94-105. doi: 10.1016/j.ejps.2016.02.002. Epub 2016 Feb 2.

PMID:
26850682
37.

Preanalytical, analytical, gestational and pediatric aspects of the S100B immuno-assays.

Bouvier D, Duret T, Rouzaire P, Jabaudon M, Rouzaire M, Nourrisson C, Bourgne C, Pereira B, Evrard B, Sapin V.

Clin Chem Lab Med. 2016 May;54(5):833-42. doi: 10.1515/cclm-2015-0771.

38.

Interest of cyclodextrins in spray-dried microparticles formulation for sustained pulmonary delivery of budesonide.

Dufour G, Bigazzi W, Wong N, Boschini F, de Tullio P, Piel G, Cataldo D, Evrard B.

Int J Pharm. 2015 Nov 30;495(2):869-78. doi: 10.1016/j.ijpharm.2015.09.052. Epub 2015 Sep 26.

PMID:
26410753
39.

2D-Cosy NMR Spectroscopy as a Quantitative Tool in Biological Matrix: Application to Cyclodextrins.

Dufour G, Evrard B, de Tullio P.

AAPS J. 2015 Nov;17(6):1501-10. doi: 10.1208/s12248-015-9806-9. Epub 2015 Aug 25.

40.

Understanding the impact of microcrystalline cellulose physicochemical properties on tabletability.

Thoorens G, Krier F, Rozet E, Carlin B, Evrard B.

Int J Pharm. 2015 Jul 25;490(1-2):47-54. doi: 10.1016/j.ijpharm.2015.05.026. Epub 2015 May 14.

PMID:
25981619
41.

Peanut oral immunotherapy in adolescents: study protocol for a randomized controlled trial.

Michaud E, Evrard B, Pereira B, Rochette E, Bernard L, Rouzaire PO, Gourdon-Dubois N, Merlin E, Fauquert JL.

Trials. 2015 Apr 29;16:197. doi: 10.1186/s13063-015-0717-y.

42.

The ReproGenomics Viewer: an integrative cross-species toolbox for the reproductive science community.

Darde TA, Sallou O, Becker E, Evrard B, Monjeaud C, Le Bras Y, Jégou B, Collin O, Rolland AD, Chalmel F.

Nucleic Acids Res. 2015 Jul 1;43(W1):W109-16. doi: 10.1093/nar/gkv345. Epub 2015 Apr 16.

43.

Rapid quantification of 2-hydroxypropyl-β-cyclodextrin in liquid pharmaceutical formulations by (1)H nuclear magnetic resonance spectroscopy.

Dufour G, Evrard B, de Tullio P.

Eur J Pharm Sci. 2015 Jun 20;73:20-8. doi: 10.1016/j.ejps.2015.03.005. Epub 2015 Mar 20.

44.

Optimization of a PGSS (particles from gas saturated solutions) process for a fenofibrate lipid-based solid dispersion formulation.

Pestieau A, Krier F, Lebrun P, Brouwers A, Streel B, Evrard B.

Int J Pharm. 2015 May 15;485(1-2):295-305. doi: 10.1016/j.ijpharm.2015.03.027. Epub 2015 Mar 18.

PMID:
25796121
45.

Optimization of a pharmaceutical tablet formulation based on a design space approach and using vibrational spectroscopy as PAT tool.

Chavez PF, Lebrun P, Sacré PY, De Bleye C, Netchacovitch L, Cuypers S, Mantanus J, Motte H, Schubert M, Evrard B, Hubert P, Ziemons E.

Int J Pharm. 2015;486(1-2):13-20. doi: 10.1016/j.ijpharm.2015.03.025. Epub 2015 Mar 16.

PMID:
25791761
46.

Vibrational spectroscopy and microspectroscopy analyzing qualitatively and quantitatively pharmaceutical hot melt extrudates.

Netchacovitch L, Thiry J, De Bleye C, Chavez PF, Krier F, Sacré PY, Evrard B, Hubert P, Ziemons E.

J Pharm Biomed Anal. 2015 Sep 10;113:21-33. doi: 10.1016/j.jpba.2015.01.051. Epub 2015 Feb 7. Review.

PMID:
25704954
47.

Development of anti-E6 pegylated lipoplexes for mucosal application in the context of cervical preneoplastic lesions.

Lechanteur A, Furst T, Evrard B, Delvenne P, Hubert P, Piel G.

Int J Pharm. 2015 Apr 10;483(1-2):268-77. doi: 10.1016/j.ijpharm.2015.02.041. Epub 2015 Feb 19.

PMID:
25701628
48.

Integrated RNA- and protein profiling of fermentation and respiration in diploid budding yeast provides insight into nutrient control of cell growth and development.

Becker E, Liu Y, Lardenois A, Walther T, Horecka J, Stuparevic I, Law MJ, Lavigne R, Evrard B, Demougin P, Riffle M, Strich R, Davis RW, Pineau C, Primig M.

J Proteomics. 2015 Apr 24;119:30-44. doi: 10.1016/j.jprot.2015.01.015. Epub 2015 Feb 4.

49.

Mucoadhesive cellulosic derivative sponges as drug delivery system for vaginal application.

Furst T, Piette M, Lechanteur A, Evrard B, Piel G.

Eur J Pharm Biopharm. 2015 Sep;95(Pt A):128-35. doi: 10.1016/j.ejpb.2015.01.019. Epub 2015 Feb 4.

PMID:
25660908
50.

Impact of the structure of biocompatible aliphatic polycarbonates on siRNA transfection ability.

Frère A, Kawalec M, Tempelaar S, Peixoto P, Hendrick E, Peulen O, Evrard B, Dubois P, Mespouille L, Mottet D, Piel G.

Biomacromolecules. 2015 Mar 9;16(3):769-79. doi: 10.1021/bm501676p. Epub 2015 Jan 30.

PMID:
25603322

Supplemental Content

Loading ...
Support Center